Zydus Sets Sight On First US Generic Of UCB’s Briviact
FDA Approves Brivaracetam ANDA With Shared 180-Day Exclusivity
Executive Summary
Zydus Cadila has scooped another material ANDA approval from the FDA, with the green light for its generic version of UCB’s Briviact to treat partial-onset seizures.